Beida pharmaceutical company: The State Food and Drug Administration has approved the company's application for listing tartaric acid teriteline capsules.

Beida Pharmaceutical announced that the State Food and Drug Administration approved the company's application for the market launch of tartaric acid Teryxili capsules, which are suitable for locally advanced or metastatic adult breast cancer patients who have progressed after previous endocrine therapy and are hormone receptor positive and human epidermal growth factor receptor 2 negative. The drug is a newly developed compound independently researched by the company, classified as a Category 1 chemical drug, and has complete independent intellectual property rights. Currently, there are seven CDK4/6 inhibitors approved in the country for the treatment of HR+/HER2- breast cancer, but Teryxili is an innovative drug that has not been launched in domestic or foreign markets. After obtaining the drug registration certificate, the company can produce and sell the drug, but the specific sales situation is subject to uncertainties such as changes in the market environment.